Scarica l'app Stockscreener
7.13
0.00%
0.00
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché TPST Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$7.13
Aprire:
$7.13
Volume 24 ore:
48,646
Relative Volume:
0.45
Capitalizzazione di mercato:
$32.70M
Reddito:
-
Utile/perdita netta:
$-31.11M
Rapporto P/E:
-4.6601
EPS:
-1.53
Flusso di cassa netto:
$-28.18M
1 W Prestazione:
+0.56%
1M Prestazione:
+4.70%
6M Prestazione:
-42.38%
1 anno Prestazione:
-74.01%
Intervallo 1D:
$7.0703
$7.18
Intervallo di 1 settimana:
$6.73
$7.18
Portata 52W:
$5.3495
$30.03
Tempest Therapeutics Inc Stock (TPST) Company Profile
Nome
Tempest Therapeutics Inc
Settore
Industria
Telefono
415-798-8589
Indirizzo
2000 SIERRA POINT PARKWAY, BRISBANE
Confronta TPST con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TPST
Tempest Therapeutics Inc
|
7.13 | 32.70M | 0 | -31.11M | -28.18M | -1.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.36 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Tempest Therapeutics Inc Stock (TPST) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-10 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-04-10 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| 2024-03-14 | Iniziato | Scotiabank | Sector Outperform |
| 2024-02-08 | Iniziato | Jefferies | Buy |
Tempest Therapeutics Inc Borsa (TPST) Ultime notizie
Millennium Management LLC Acquires Shares of 189,506 Tempest Therapeutics, Inc. (NASDAQ:TPST) - Defense World
Tempest Therapeutics Secures $4.1M in Direct Offering - TipRanks
SEC Form 424B5 filed by Tempest Therapeutics Inc. - Quantisnow
Form 424B5 Tempest Therapeutics, - StreetInsider
Tempest Therapeutics Announces $4.6 Mln Registered Direct Offering With Institutional Investor - Nasdaq
Tempest Therapeutics (TPST) Announces New Stock Purchase Agreeme - GuruFocus
Tempest Therapeutics ends ATM prospectus with Jefferies By Investing.com - Investing.com Canada
Tempest Announces $4.6 Million Registered Direct Offering of Common Stock - The Manila Times
Tempest Therapeutics, Inc. Announces $4.6 Million Registered Direct Offering of Common Stock - Nasdaq
Tempest Therapeutics announces $4.6 million registered direct offering - Investing.com
Tempest Therapeutics ends ATM prospectus with Jefferies - Investing.com
Tempest Therapeutics Terminates ATM Prospectus Supplement Dated February 6, 2025SEC Filing - MarketScreener
Why Circle Internet Group Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket - Benzinga
Pre-market Movers: KLTO, TPST, PYPD, MOVE... - RTTNews
Tempest Therapeutics Shifts Executives to Consulting Roles - TipRanks
Tempest Therapeutics stock rises on EMA Orphan Drug Designation By Investing.com - Investing.com South Africa
Tempest Therapeutics stock rises on EMA Orphan Drug Designation - Investing.com
Tempest Therapeutics Says Amezalpat Gets EMA Orphan Drug Designation in Liver Cancer - marketscreener.com
Tempest Therapeutics: European Medicines Agency Grants Orphan Drug Designation To Amezalpat - Nasdaq
TPST Receives EMA Orphan Drug Designation for Liver Cancer Treatment | TPST Stock News - GuruFocus
Tempest Receives Orphan Drug Designation from the European - GlobeNewswire
Tempest Therapeutics Reports Q1 2025 Financial Results - TipRanks
HC Wainwright Issues Optimistic Estimate for TPST Earnings - Defense World
Tempest Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Layoff Tracker: Allogene Cuts 28% of Staff to Extend Runway, Focus on Clinical Programs - BioSpace
TPST Highlights Promising Data for Cancer Therapy | TPST Stock N - GuruFocus
Tempest Reports First Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Tempest Therapeutics Q1 Operating Income USD -10.936 Million - marketscreener.com
Tempest Therapeutics Reports Positive Amezalpat Data and FDA Designations for Cancer Treatment Programs - Nasdaq
FDA Grants Multiple Key Designations to Tempest Cancer Drugs as New AACR Data Shows Promise - Stock Titan
Millendo Therapeutics, Inc. Announces Board Changes - marketscreener.com
Cash-strapped Bay Area biotech company lays off all but 5 employees - MSN
Tempest Therapeutics Inc expected to post a loss of $3.29 a shareEarnings Preview - TradingView
Geode Capital Management LLC Has $296,000 Stake in Tempest Therapeutics, Inc. (NASDAQ:TPST) - Defense World
TPSTTempest Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
XTX Topco Ltd Has $134,000 Position in Tempest Therapeutics, Inc. (NASDAQ:TPST) - Defense World
Tempest Therapeutics regains Nasdaq compliance By Investing.com - Investing.com Canada
Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting - The Manila Times
Tempest Therapeutics Presents Promising Amezalpat Data at 2025 AACR Annual Meeting, Supporting Novel Cancer Treatment Mechanism - Nasdaq
Tempest Presents New Amezalpat MOA Data Reinforcing Its - GlobeNewswire
Breakthrough: New Cancer Drug Amezalpat Demonstrates Dual Anti-Cancer Mechanism in Multiple Tumors - Stock Titan
Tempest Therapeutics regains Nasdaq compliance - Investing.com
Market Recap Check: Tempest Therapeutics Inc (TPST)’s Negative Finish at 0.61, Up/Down -14.53 - DWinneX
Struggling Bay Area biotech company, once worth $1B, lays off all but 5 workers - SFGATE
Tempest Therapeutics - The Pharma Letter
Tempest Therapeutics stock rises on FDA Orphan Drug Designation By Investing.com - Investing.com Nigeria
Tempest Therapeutics stock rises on FDA Orphan Drug Designation - Investing.com Australia
Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP - The Manila Times
Tempest Therapeutics Inc Azioni (TPST) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Tempest Therapeutics Inc Azioni (TPST) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Versant Venture Capital VI, L. | 10% Owner |
Aug 08 '24 |
Sale |
1.35 |
400,000 |
540,040 |
597,940 |
| Versant Venture Capital VI, L. | 10% Owner |
Aug 12 '24 |
Sale |
1.10 |
387,999 |
426,993 |
209,941 |
0.68%
0.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):